Eikonizo Therapeutics

Eikonizo Therapeutics, founded in 2017, is a biotechnology company based in the United States that is committed to envisioning an end to neurodegenerative diseases. The company's mission is to develop life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Their pioneering efforts are focused on a disease-modifying therapeutic for neurodegenerative diseases. In April 2018, Eikonizo Therapeutics secured a $2.00M investment in a Seed Round. Although specific investors for this round are not disclosed, this investment underscores the growing support and interest in the company's innovative approach within the biotechnology, health care, and pharmaceutical industries. Eikonizo's dedication to addressing the pressing needs in neurodegenerative diseases positions the company as an impactful player in the biotech industry.